PHD Inhibitors

Featured articles on the clinical use of compounds that target the HIF oxygen sensing pathway for therapy. PHD inhibitors, sometimes referred to as PHIs or HIF-PHIs, are structural analogs of 2-oxoglutarate and are currently in phase 3 clinical development for the treatment of renal anemia.